Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1866333 | 0.84 | HTT (0.42) | ACACBMAPK1ALDH1A1CYP3A4HPGD | |
| SCHEMBL5730137 | 0.84 | CYP1A2 (0.44) | ALDH1A1CYP3A4HTTNPSR1MAPT | |
| SCHEMBL5102368 | 0.82 | HTT (0.41) | ACACBMAPK1ALDH1A1CYP3A4HPGD | |
| Potassium SCHEMBL5102369 | 0.82 | HTT (0.41) | ACACBMAPK1ALDH1A1CYP3A4HPGD | |
| SCHEMBL6049469 | 0.81 | ALDH1A1 (0.47) | ALDH1A1HTTMAPTMEN1LMNA | |
| SCHEMBL30211225 | 0.79 | MDM2 (0.41) | ALDH1A1HPGDMDM2LMNA | |
| SCHEMBL157185 | 0.79 | MDM2 (0.41) | ALDH1A1HPGDMDM2LMNA | |
| SCHEMBL12630667 | 0.78 | HPGD (0.38) | ACACBJAK2TYK2HTR2ASLC6A4 | |
| SCHEMBL837745 | 0.77 | ESR2 (0.37) | S1PR1S1PR3JAK2TYK2MDM2 | |
| SCHEMBL3687105 | 0.76 | SLC6A4 (0.44) | ACACBHTR2ASLC6A4KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531490-B1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2014-10-15 | — | — | EP | disclosed |
| US-8835444-B2 | Cyclohexyl amide derivatives as CRF receptor antagonists | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| US-20120316185-A1 | Cyclohexyl Amide Derivatives as CRF Receptor Antagonists | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| EP-2531490-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| EP-1832590-B1 | Heterotricyclic compounds as CRF receptor antagonists | ONO PHARMACEUTICAL CO (JP) | 2011-09-28 | — | — | EP | disclosed |
| EP-1832590-B1 | Heterotricyclic compounds as CRF receptor antagonists | ONO PHARMACEUTICAL CO (JP) | 2011-09-28 | — | — | EP | disclosed |
| WO-2011095450-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| US-7947697-B1 | 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d] pyrazolo[1,5-a]pyrimidine methanesulfonate as a CRF antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-7947697-B1 | 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d] pyrazolo[1,5-a]pyrimidine methanesulfonate as a CRF antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-7807688-B2 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-7459459-B2 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-02 | — | — | US | disclosed |
| US-7459459-B2 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-02 | — | — | US | disclosed |
| EP-1354884-B1 | CYCLOPENTA[D]PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND AS CRF RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO (JP) | 2007-10-10 | — | — | EP | disclosed |
| EP-1832590-A2 | Tri- heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-09-12 | — | — | EP | disclosed |
| EP-1832590-A2 | Tri- heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-09-12 | — | — | EP | disclosed |
| US-20060122392-A1 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2006-06-08 | — | — | US | disclosed |
| US-7034153-B2 | Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-04-25 | — | — | US | disclosed |
| EP-1637531-A1 | METHANESULFONIC ACID SALT OF PYRAZOLOPYRIMIDINE COMPOUND, CRYSTAL THEREOF, AND PROCESS FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20040072833-A1 | Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1354884-A1 | TRICYCLIC AND HETEROCYCLIC DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122392-A1 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | NR3C1, CRHR2, CRHR1 | ACACB 3427/4885S1PR1 2018/4885S1PR3 1341/4885 |
| US-20120316185-A1 | Cyclohexyl Amide Derivatives as CRF Receptor Antagonists | CRHR2, CRHR1, CRH | ACACB 2515/4885S1PR1 771/4885S1PR3 782/4885 |
| US-20040072833-A1 | Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient | CRH, CRHR1, CRHR2 | ACACB 3527/4885S1PR1 1545/4885S1PR3 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.